<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372382</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0777</org_study_id>
    <nct_id>NCT03372382</nct_id>
  </id_info>
  <brief_title>Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section</brief_title>
  <acronym>IVY</acronym>
  <official_title>Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section: A Prospective, Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum patients delivered by cesarean section will be randomized to NSAIDS Vs NSAIDS plus
      opioid
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be approached priors to discharge from the hospital, if they meet inclusion
      criteria and consent for the study, they will be randomized to one of two possible analgesic
      regimens. They will be followed at 1-2 weeks and 4-6 weeks after discharge to assess pain
      level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two parallel groups included, randomized to control analgesic regimen versus alternative analgesic regimen and followed prospectively.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Level</measure>
    <time_frame>2-4 weeks postpartum</time_frame>
    <description>pain level measured by objective and subjective scales.
1- Objective scale: visual analogue pain score (VAS). It is a 100 mm line, patients will be instructed to mark a point in the line that represents their pain level. A point towards the left will mean &quot;less pain&quot; and a point towards the right will mean &quot;more pain&quot;. After the patient makes a selection, the research team will measure where the selected point is (in cm). minimum measurement =0mm = no pain. maximum measurement=100mm=worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>2-4 weeks postpartum</time_frame>
    <description>patient satisfaction as measured by the following scale: 1(very dissatisfied) 2(somewhat dissatisfied) 3(neutral) 4(satisfied) 5(very satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Opioid Use</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>ibuprofen plus acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen plus acetaminophen/hydrocodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>NSAID</description>
    <arm_group_label>ibuprofen plus acetaminophen</arm_group_label>
    <arm_group_label>ibuprofen plus acetaminophen/hydrocodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>analgesic</description>
    <arm_group_label>ibuprofen plus acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norco</intervention_name>
    <description>acetaminophen plus opioid</description>
    <arm_group_label>ibuprofen plus acetaminophen/hydrocodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English or Spanish speaker women who had a cesarean section

        Exclusion Criteria:

          -  Inability or refusal to provide informed consent.

          -  Reported current or prior opioid or benzodiazepine use disorder, including urine drug
             screen positive for a non prescribed opioid or benzodiazepine upon admission or during
             prenatal care.

          -  Current treatment with methadone, buprenorphine or buprenorphine plus naloxone.

          -  Known alcoholism disorder.

          -  Severe renal or hepatic impairment.

          -  Known creatinine &gt; 1.5 at the time of delivery or severe proteinuria leading to
             diagnosis of renal disease prior to delivery.

          -  Severe peptic ulcer disease

          -  Severe asthma (if patient has asthma but has previously tolerated NSAIDS, she will be
             allowed to participate)

          -  Known CYP450/CY92D6 mutation conferring opioid ultra-rapid metabolizer status.

          -  Allergy to any of the study drugs (anaphylaxis).

          -  Incarcerated or institutionalized patients.

          -  Inability to follow up as outpatient in our outpatient clinic.

          -  wound dehiscence or infection diagnosed prior to discharge from the hospital

          -  wound vac placed prior to discharge from the hospital
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>study will be conducted among subjects who delivered by cesarean section, which by definition, are only females.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenifer Dinis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Houston, McGovern Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 9, 2017</study_first_submitted>
  <study_first_submitted_qc>December 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>June 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jenifer Dinis Ballestas</investigator_full_name>
    <investigator_title>MD, Maternal Fetal Medicine Fellow</investigator_title>
  </responsible_party>
  <keyword>postpartum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03372382/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment start date: 12/2017 recruitment end date: 03/2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen Plus Acetaminophen</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
Ibuprofen: NSAID
Acetaminophen: analgesic
85 women recruited into this study arm</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen Plus Acetaminophen/Hydrocodone</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone
Ibuprofen: NSAID
Acetaminophen plus hydrocodone: Opioid
85 women recruited into this study arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibuprofen Plus Acetaminophen</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
Ibuprofen: NSAID
Acetaminophen: analgesic
85 women recruited into this study arm</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen Plus Acetaminophen/Hydrocodone</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone
Ibuprofen: NSAID
Acetaminophen plus hydrocodone: Opioid
85 women recruited into this study arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.39" spread="5.8"/>
                    <measurement group_id="B2" value="28.05" spread="5.64"/>
                    <measurement group_id="B3" value="28.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>African american</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Level</title>
        <description>pain level measured by objective and subjective scales.
1- Objective scale: visual analogue pain score (VAS). It is a 100 mm line, patients will be instructed to mark a point in the line that represents their pain level. A point towards the left will mean &quot;less pain&quot; and a point towards the right will mean &quot;more pain&quot;. After the patient makes a selection, the research team will measure where the selected point is (in cm). minimum measurement =0mm = no pain. maximum measurement=100mm=worst pain.</description>
        <time_frame>2-4 weeks postpartum</time_frame>
        <population>The primary outcome was available in 71 patients in the non-opioid group and 76 patients in the opioid group. The results below are primary outcome data analyzed by intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen Plus Acetaminophen</title>
            <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
Ibuprofen: NSAID
Acetaminophen: analgesic</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Plus Acetaminophen/Hydrocodone</title>
            <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
Ibuprofen: NSAID
Norco: acetaminophen plus opioid</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Level</title>
          <description>pain level measured by objective and subjective scales.
1- Objective scale: visual analogue pain score (VAS). It is a 100 mm line, patients will be instructed to mark a point in the line that represents their pain level. A point towards the left will mean &quot;less pain&quot; and a point towards the right will mean &quot;more pain&quot;. After the patient makes a selection, the research team will measure where the selected point is (in cm). minimum measurement =0mm = no pain. maximum measurement=100mm=worst pain.</description>
          <population>The primary outcome was available in 71 patients in the non-opioid group and 76 patients in the opioid group. The results below are primary outcome data analyzed by intention to treat.</population>
          <units>millimeters on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="19.5"/>
                    <measurement group_id="O2" value="15.9" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size calculations were based on VAS pain score at 2-4 weeks, assuming a mean of 10mm and standard deviation (SD) of 20 mm in the opioid group Assuming a two-sided alpha level of 0.05 and 80% power to detect equivalence, a total of 138 participants would be needed. To account for a 25% expected attrition rate and crossover, a total of 170 participants would be needed.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>We prespecified an equivalence margin of -10 to 10mm. We would consider non-opioid analgesia to be equivalent to opioid analgesia if the pain score mean difference between the groups and itâ€™s 95% confidence interval (CI) were within the prespecified margin. Pain score mean difference or 95% CI boundaries outside this range would be considered a clinically important difference between treatments</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
            <estimate_desc>The upper boundary of the CI is out of pre-specified limits.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>patient satisfaction as measured by the following scale: 1(very dissatisfied) 2(somewhat dissatisfied) 3(neutral) 4(satisfied) 5(very satisfied)</description>
        <time_frame>2-4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen Plus Acetaminophen</title>
            <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
Ibuprofen: NSAID
Acetaminophen: analgesic
85 women recruited into this study arm</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen Plus Acetaminophen/Hydrocodone</title>
            <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone
Ibuprofen: NSAID
Acetaminophen plus hydrocodone: Opioid
85 women recruited into this study arm</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>patient satisfaction as measured by the following scale: 1(very dissatisfied) 2(somewhat dissatisfied) 3(neutral) 4(satisfied) 5(very satisfied)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1(very dissatisfied)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2(somewhat dissatisfied)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3(neutral)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4(satisfied)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5(very satisfied)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>four months</time_frame>
      <desc>a standard questionnaire was used to assess whether any adverse events had occurred. It was administered at the time of follow up.
Medical records were also reviewed to determine if a patient had an adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibuprofen Plus Acetaminophen</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
Ibuprofen: NSAID
Acetaminophen: analgesic
85 women recruited into this study arm</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen Plus Acetaminophen/Hydrocodone</title>
          <description>women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone
Ibuprofen: NSAID
Acetaminophen plus hydrocodone: Opioid
85 women recruited into this study arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea / emesis</sub_title>
                <description>non-opioid group: 2 opioid group: 5</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>constipation</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <description>reflux</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <description>somnolence</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>itching</sub_title>
                <description>itching</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jenifer Dinis, MD</name_or_title>
      <organization>McGovern Medical School, University of Texas, Health Science Center at Houston</organization>
      <phone>713 500 6421</phone>
      <email>jenifer.dinis@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

